Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant.
The potential of tumor cells (J558L) engineered to produce one of 5 different cytokines (interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or gamma-interferon) to give rise to systemic immunity protective against a contralateral challenge with the parental cells was analyzed. The rejection of all cytokine-producing cells appeared to induce some systemic response capable of mediating the rejection of low numbers of subsequently contralaterally injected cells, but the effect was much less obvious with higher cell numbers. The injection of any possible combination of two of the cytokine producers did not reveal any synergistic effects. The cytokine gene-transfected tumor cells were not superior to the parental cells admixed with the adjuvant Corynebacterium parvum with respect to their potential as immunogens to induce immunity.
Hock
H
H
Institute of Immunology, Free University of Berlin, Germany.
Dorsch
M
M
Kunzendorf
U
U
Uberla
K
K
Qin
Z
Z
Diamantstein
T
T
Blankenstein
T
T
D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage*; D004357:Drug Synergism; D005260:Female; D007372:Interferons / Q000096:biosynthesis* / Q000235:genetics; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics; D015847:Interleukin-4 / Q000096:biosynthesis* / Q000235:genetics; D015851:Interleukin-7 / Q000096:biosynthesis* / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010954:Plasmacytoma / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000517:prevention & control*; D014162:Transfection; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D001500:BCG Vaccine; D007376:Interleukin-2; D015851:Interleukin-7; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007372:Interferons